Beam Therapeutics BEAM EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's EPS (diluted)?
- Beam Therapeutics (BEAM) reported EPS (diluted) of -$0.91 in Q1 2026.
- How has Beam Therapeutics's EPS (diluted) changed year-over-year?
- Beam Therapeutics's EPS (diluted) increased by 26.0% year-over-year, from -$1.23 to -$0.91.
- What is the long-term trend for Beam Therapeutics's EPS (diluted)?
- Over 2 years (2021 to 2024), Beam Therapeutics's EPS (diluted) has grown at a -12.0% compound annual growth rate (CAGR), from -$5.91 to -$4.58.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.